2026 SOHO Brazil meeting attracts nearly 1,000 attendees
Held annually in São Paulo, SOHO Brazil is part of the SOHO Ambassador Program, which supports regional meetings around the world to expand
Ambassador Program
News
Multiple Myeloma
News
Clinical use assay launched for MRD detection in myeloma
The assay supports treatment evaluation and risk stratification by detecting residual disease or early reemergence that standard testing might miss.
EHA 2026
Meetings / Conferences
Myelodysplastic Syndromes
Video Interviews
Updated phase 2 trial results of elritercept in patients with LR-MDS
Dr. Campelo outlines safety and efficacy data for this novel TGF-beta pathway inhibitor, highlighting transfusion independence rates, overall response rates, and safety outcomes
Multiple Myeloma
News
Phase 3 trial finds no survival benefit for indefinite maintenance in multiple myeloma
The trial enrolled patients with standard-risk disease who were not undergoing up-front autologous stem-cell transplantation. Following induction treatment with a proteasome inhibitor–lenalidomide combination,
ASCO 2026
Trending now
Meetings / Conferences
Myeloproliferative Neoplasms
News
Selinexor plus ruxolitinib meaningfully improves spleen response in MF trial
In this video from the 2026 ASCO Annual Meeting, Dr. Mascarenhas, a Professor of Medicine at the Icahn School of Medicine at Mount
EHA 2026
Meetings / Conferences
Myelodysplastic Syndromes
Video Interviews
Varun Bafna, MD, discusses phase 2 results of ofirnoflast in LR-MDS
Ofirnoflast, a first-in-class, oral, allosteric inhibitor of NEK7, was evaluated in 37 patients and demonstrated clinically meaningful results, according to the investigators, who
Focus on CELMoDs
EHA 2026
Meetings / Conferences
Multiple Myeloma
Roundtable Discussions
Video Interviews
The promise of CELMoDs in myeloma treatment
The speakers highlighted how combining these powerful drugs into fixed-duration regimens could help patients achieve long-term remissions and move closer to a cure.
EHA 2026
Meetings / Conferences
Multiple Myeloma
Video Interviews
EHA 2026 updates on the phase 3 MajesTEC-3 trial and MonumenTAL-3 trials
The panel also discussed the success of combining teclistamab and daratumumab for functional high-risk patients who historically experience poor outcomes.
Focus on CELMoDs
EHA 2026
Meetings / Conferences
Multiple Myeloma
Roundtable Discussions
Video Interviews
Intergrating CELMoDs with other therapies in myeloma
The panel also discussed the therapeutic potential of these combinations. Dr. Banerjee highlighted the role of CELMoDs in post-CAR T care, noting that
ASCO 2026
Trending now
Meetings / Conferences
Myeloproliferative Neoplasms
Primary Myelofibrosis
Video Interviews
Andrew Kuykendall, MD, discusses updated data from the RALLY-MF trial
Andrew Kuykendall, MD, an associate member from Moffitt Cancer Center, discusses updated data from the phase 2 RALLY-MF trial. The trial evaluated DISC-0974